Correspondence

Psychological Medicine, 46 (2016).
doi:10.1017/S0033291716001124
First published online 13 June 2016

Letter to the Editor
Postpartum psychosis and pre-eclamptic toxaemia: a reply

Brockington (2016) highlights the co-occurrence of eclampsia and postpartum psychosis as an important diagnostic consideration. We agree and have described in our previous work the importance of performing thorough physical, neurological and laboratory examinations of every patient with first-onset postpartum psychosis as this might lead to a diagnosis with treatable causes and comorbidities (Bergink et al. 2015b). In addition to eclampsia, clinicians should consider the postpartum occurrence of autoimmune disorders (e.g. thyroiditis), encephalitis (e.g. NMDA encephalitis), infections (e.g. endometritis, mastitis) and rare inborn errors of metabolism.

Most women with first-onset postpartum psychosis will exhibit one of two disease courses (Bergink et al. 2015a): an isolated postpartum psychosis with vulnerability to affective psychosis only after birth or postpartum psychosis as an expression of bipolar mood disorder with non-perinatal episodes (Chaudron & Pies, 2003; Di Florio et al. in press). The diagnostic criteria for puerperal bipolar disorder and Donkin psychosis as described by Brockington (2016) have neither been validated nor field tested, and therefore are not currently suitable for implementation in population-based epidemiological studies.

References


V. BERGINK 1,2,*, T. M. LAURSEN 1,3, B. M. W. JOHANNSSEN 2, S. M. MELTZER-BRODY 4 AND T. MUNK-OLSEN 1
1 National Center for Register-Based Research, Aarhus School of Business and Social Sciences, Aarhus University, Aarhus, Denmark
2 Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands
3 CIRRAU, Centre for Integrated Register-based Research, Aarhus School of Business and Social Sciences, Aarhus University, Aarhus, Denmark
4 Department of Psychiatry, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

*Author for correspondence: Dr V. Bergink, Department of Psychiatry, Erasmus Medical Center, 5’s Gravendijkwal 230, 3000 CA, Rotterdam, The Netherlands.
(Email: v.bergink@erasmusmc.nl)